|
🐜
|
The impact of second to sixth line therapy on survival of relapsed ovarian cancer after primary taxane/platinum-based therapy.
10 auth.
Lars Hanker,
S. Loibl,
N. Burchardi,
J. Pfisterer,
W. Meier,
E. Pujade-Lauraine,
...
I. Ray-Coquard,
J. Sehouli,
P. Harter,
A. D. Bois
|
8 |
2012 |
8
🐜
|
|
🐜
|
A phase II trial (AGO 2.11) in platinum-resistant ovarian cancer: a randomized multicenter trial with sunitinib (SU11248) to evaluate dosage, schedule, tolerability, toxicity and effectiveness of a multitargeted receptor tyrosine kinase inhibitor monotherapy.
17 auth.
K. Baumann,
A. Bois,
W. Meier,
J. Rau,
P. Wimberger,
J. Sehouli,
C. Kurzeder,
F. Hilpert,
A. Hasenburg,
U. Canzler,
...
L. Hanker,
Peter Hillemanns,
B. Richter,
K. Wollschlaeger,
T. Dewitz,
Dirk Bauerschlag,
Uwe Wagner
|
6 |
2012 |
6
🐜
|
|
🐜
|
Carboplatin/paclitaxel versus cisplatin/paclitaxel as first-line chemotherapy in advanced ovarian cancer: an interim analysis of a randomized phase III trial of the Arbeitsgemeinschaft Gynäkologische Onkologie Ovarian Cancer Study Group.
12 auth.
A. D. Bois,
Hans-Joachim Lück,
W. Meier,
Volker Möbus,
Serban D. Costa,
B. Richter,
...
Mathias Warm,
Thomas Bauknecht,
W. Schröder,
S. Olbricht,
U. Nitz,
C. Jackisch
|
6 |
1997 |
6
🐜
|
|
🐜
|
Age-dependent differences in borderline ovarian tumours (BOT) regarding clinical characteristics and outcome: results from a sub-analysis of the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) ROBOT study.
31 auth.
F. Trillsch,
S. Mahner,
L. Woelber,
Eik Vettorazzi,
A. Reuss,
N. Ewald-Riegler,
N. Gregorio,
C. Fotopoulou,
B. Schmalfeldt,
Alexander Burges,
F. Hilpert,
T. Fehm,
W. Meier,
P. Hillemanns,
L. Hanker,
...
A. Hasenburg,
H. Strauß,
M. Hellriegel,
P. Wimberger,
K. Baumann,
M. Keyver-Paik,
U. Canzler,
K. Wollschlaeger,
D. Forner,
J. Pfisterer,
W. Schroeder,
K. Muenstedt,
B. Richter,
F. Kommoss,
Steffen Hauptmann,
A. Bois
|
5 |
2014 |
5
🐜
|
|
🐜
|
Chemotherapy versus hormonal treatment in platinum- and paclitaxel-refractory ovarian cancer: a randomised trial of the German Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) Study Group Ovarian Cancer.
12 auth.
A. Bois,
W. Meier,
H. Lück,
Günter Emons,
V. Moebus,
W. Schroeder,
...
S. Costa,
Thomas Bauknecht,
S. Olbricht,
C. Jackisch,
B. Richter,
U. Wagner
|
5 |
2002 |
5
🐜
|
|
🐜
|
First-line chemotherapy with epirubicin, paclitaxel, and carboplatin for advanced ovarian cancer: a phase I/II study of the Arbeitsgemeinschaft Gynäkologische Onkologie Ovarian Cancer Study Group.
8 auth.
A. D. Bois,
Hans-Joachim Lück,
Thomas Bauknecht,
W. Meier,
B. Richter,
Walther Kuhn,
...
J. Quaas,
J. Pfisterer
|
5 |
1999 |
5
🐜
|
|
🐜
|
Quality of life in patients with advanced epithelial ovarian cancer (EOC) randomized to maintenance pazopanib or placebo after first-line chemotherapy in the AGO-OVAR 16 trial. Measuring what matters—patient-centered end points in trials of maintenance therapy
21 auth.
M. Friedlander,
J. Rau,
Chee Khoon Lee,
W. Meier,
A. Lesoin,
J. Kim,
A. Poveda,
M. Buck,
Giovanni Scambia,
M. Shimada,
...
F. Hilpert,
M. King,
P. Debruyne,
A. Bologna,
S. Malander,
B. Monk,
Edgar Petru,
Paula M Calvert,
Thomas J. Herzog,
C. Barrett,
A. Bois
|
4 |
2017 |
4
🐜
|
|
🐜
|
Prognostic factors in young ovarian cancer patients: An analysis of four prospective phase III intergroup trials of the AGO Study Group, GINECO and NSGO.
10 auth.
Maximilian Klar,
A. Hasenburg,
M. Hasanov,
F. Hilpert,
W. Meier,
J. Pfisterer,
...
E. Pujade-Lauraine,
Jørn Herrstedt,
A. Reuss,
A. D. Bois
|
4 |
2016 |
4
🐜
|
|
🐜
|
Randomized phase III study to evaluate the impact of secondary cytoreductive surgery in recurrent ovarian cancer: Final analysis of AGO DESKTOP III/ENGOT-ov20.
20 auth.
A. du Bois,
J. Sehouli,
I. Vergote,
Gwenael Ferron,
A. Reuss,
W. Meier,
S. Greggi,
Pernille T Jensen,
F. Selle,
F. Guyon,
...
C. Pomel,
Fabrice Lécuru,
R. Zang,
E. Åvall-Lundqvist,
Jae-Weon Kim,
J. Ponce,
F. Raspagliesi,
S. Ghaem-Maghami,
Alexander Reinthaller,
P. Harter
|
4 |
2020 |
4
🐜
|
